Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2011. The report serves as a correction to previous notifications regarding the GlaxoSmithKline Performance Share Plan. It addresses an administrative error in the market price used to calculate notional share interests for dividend reinvestment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the correction of share plan calculations and does not contain consolidated financial statements or operational metrics.
Material Changes
The primary material change disclosed is a correction to the market price of Ordinary shares used for the dividend reinvestment element of the Performance Share Plan for dividends paid on April 7, 2011. The price was erroneously recorded as £12.22 instead of 1216.50 pence. This correction resulted in amended notional share interests for affected participants and had a minor cumulative impact on calculations for subsequent dividends paid on July 7, 2011, and October 6, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. The only risk or contingency noted is the administrative error in share pricing, which has been rectified. The document confirms that, save for the disclosed amendments, all other details remain unchanged.
Investor Verification Checklist
- Verify the corrected notional share interests for directors and connected persons listed in the amended tables.
- Confirm that the market price of 1216.50 pence was applied to the April 7, 2011 dividend reinvestment.
- Review the cumulative impact of the correction on July and October 2011 dividend reinvestment calculations.
- Note that this filing does not contain financial performance data; refer to the company's Form 20-F for annual financial results.